ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company, announced on July 3, 2025, the issuance of inducement grants to a new non-executive employee, effective from July 1, 2025. As part of the compensation package, the employee received 9,000 non-qualified stock options and 1,600 restricted stock units, approved by ORIC's Compensation Committee under Nasdaq Rule 5635(c)(4). The stock options have an exercise price set at the closing price of ORIC's common stock on the grant date. Vesting terms for the stock options include 25% vesting after one year and the remainder vesting monthly over the following three years, while the restricted stock units vest in equal parts over three years. These grants were made under the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。